{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:48:10Z","timestamp":1767926890697,"version":"3.49.0"},"reference-count":13,"publisher":"American Medical Association (AMA)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,10,17]]},"DOI":"10.1001\/jama.2023.15087","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T15:32:23Z","timestamp":1695915143000},"page":"1433","source":"Crossref","is-referenced-by-count":4,"title":["Novel Treatments for Hereditary ATTRv Amyloidosis"],"prefix":"10.1001","volume":"330","author":[{"given":"Alejandra","family":"Gonz\u00e1lez-Duarte","sequence":"first","affiliation":[{"name":"Department of Neurology, New York University Grossman School of Medicine, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"10","key":"jed230066r1","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1007\/s00415-020-09962-6","article-title":"Chance or challenge, spoilt for choice? new recommendations on diagnostic and therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy: the German\/Austrian position and review of the literature.","volume":"268","author":"Dohrn","year":"2021","journal-title":"J Neurol"},{"key":"jed230066r2","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.amjmed.2022.01.002","article-title":"Developing therapy for transthyretin amyloidosis.","volume":"135","author":"Campbell","year":"2022","journal-title":"Am J Med"},{"issue":"3","key":"jed230066r3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","article-title":"Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis.","volume":"29","author":"Ando","year":"2022","journal-title":"Amyloid"},{"issue":"1","key":"jed230066r4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"jed230066r5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy.","author":"Coelho","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"jed230066r6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis.","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"jed230066r7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/14656566.2020.1811850","article-title":"Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.","volume":"22","author":"Gorevic","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"jed230066r8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis.","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"jed230066r9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12883-017-0948-5","article-title":"Trial design and rationale for APOLLO, a phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.","volume":"17","author":"Adams","year":"2017","journal-title":"BMC Neurol"},{"issue":"1","key":"jed230066r10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40120-021-00235-6","article-title":"Design and rationale of the global phase 3 NEURO-TTRansform study of antisense oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in hereditary transthyretin-mediated amyloid polyneuropathy.","volume":"10","author":"Coelho","year":"2021","journal-title":"Neurol Ther"},{"issue":"8","key":"jed230066r11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1080\/17512433.2019.1635008","article-title":"Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.","volume":"12","author":"Gertz","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"jed230066r12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40120-022-00414-z","article-title":"Characteristics of patients with hereditary transthyretin amyloidosis\u2013polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an open-label phase 3 study of eplontersen.","volume":"12","author":"Coelho","year":"2023","journal-title":"Neurol Ther"},{"key":"jed230066r13","unstructured":"Karam C, Gilmore J, Chen G, et al. A Multi-Method Approach to an Indirect Treatment Comparison of Eplontersen and Vutrisiran for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy. Professional Society for Health Economics and Outcomes Research (ISPOR). Published 2023. Accessed September 12, 2023. https:\/\/www.ispor.org\/docs\/default-source\/intl2023\/ispor23chenposter123926-pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2810250\/jama_gonzlezduarte_2023_ed_230066_1697145082.33972.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T15:04:01Z","timestamp":1697555041000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2810250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":13,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,10,17]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.15087","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,17]]}}}